Search Results - "Khalid, J.M"

Patients With COPD who Initiate Roflumilast in Sweden by Khalid, J.M, Mushnikov, V, Vattulainen, P, Johansson, G, Korhonen, P, Hoti, F

Get full text

PSS33 Treatment Patterns of Biologic Use in Psoriasis Patients in England by Khalid, J.M, Fox, K.M, Globe, G, Maguire, A, Chau, D

Get full text

Incidence and Prevalence of COPD By Gold 2013 Classification in the Netherlands by Van den Berg, E.J, Overbeek, J.A, Penning-van Beest, F.J.A, Khalid, J.M, Dekhuijzen, P.N.R, Herings, R

Get full text

PSY6 The Health Improvement Network (Thin) 2008-2009 Estimates of Psoriasis Incidence and Prevalence in Uk Primary Care by Khalid, J.M, Globe, G, Fox, K.M, Chau, D, Maguire, A

Get full text

PCN19 The Broader Burden of HPV-related Disease in England: A Preliminary Analysis by Khalid, J.M, Amelio, J.M, Carroll, S.M, Charman, F, Maguire, A

Get full text

PRS20 A Multinational Assessment of Direct and Indirect Costs from a Survey of Patients with Idiopathic Pulmonary Fibrosis (IPF) by Coteur, G., Mumford, A., English, B., Small, M., Siddall, J., Khalid, J.M., Langley, J.

Get full text

PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS: THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTS by Schmetz, A., Petrakis, I., Khalid, J.M., Minda, K., Agboton, C., Rawson, K., Baumgart, D.C.

Get full text

P305 Indirect comparison of two novel biologics for the treatment of Crohn's disease : network-meta analysis of ustekinumab vs vedolizumab by Hather, G., Curtis, R., Minda, K., Zouraq, I.A., Khalid, J.M.

Get full text

P470 Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with inflammatory bowel disease within 12 months of initiation of vedolizumab or infliximab by Alam, N., Raluy-Callado, M., Gardstein, B., Curtis, R., Khalid, J.M.

Get full text

P442 Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience by Feagan, B., Bhayat, F., Khalid, J.M., Palo, W., Blake, A., Shetzline, M., Travis, S.

Get full text

P466 Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis by Schreiber, S., Dignass, A., Peyrin-Biroulet, L., Hather, G., Demuth, D., Khalid, J.M., Loftus, E.V.

Get full text

PRS12 - Incidence and Prevalence of COPD By Gold 2013 Classification in the Netherlands by Van den Berg, E.J., Overbeek, J.A., Penning-van Beest, F.J.A., Khalid, J.M., Dekhuijzen, P.N.R., Herings, R.

Get full text

PRS14 - Patients With COPD who Initiate Roflumilast in Sweden by Khalid, J.M., Mushnikov, V., Vattulainen, P., Johansson, G., Korhonen, P., Hoti, F.

Get full text

DOP022 Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review by Ehehalt, R., Schubert, S., Stein, D., Lambrelli, D., Bassel, M., Orzechowski, H.-D., Minda, K., Khalid, J.M.

Get full text

DOP019 Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s disease: a GEMINI 2 post hoc analysis by Feagan, B.G., Sandborn, W.J., Colombel, J.-F., O’Byrne, S., Khalid, J.M., Brayshaw, N., Geransar, P., Rubin, D.T.

Get full text

DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters by Stallmach, A., Bokemeyer, B., Axler, J., Curtis, R., Ehehalt, R., Feagan, B., Geransar, P., James, A., Kaviya, A., Khalid, J.M., Wolf, D., Schreiber, S.

Get full text

DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study by Vermeire, S., Loftus, E.V., Colombel, J.-F., Feagan, B., Sandborn, W., Sands, B., Danese, S., D'Haens, G., Kaser, A., Panaccione, R., Rubin, D., Shafran, I., O'Byrne, S., Geransar, P., Previtali, A., Khalid, J.M., Kaviya, A.

Get full text

P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study by Loftus, E.V., Colombel, J.-F., Feagan, B., Vermeire, S., Sandborn, W., Sands, B., Danese, S., D'Haens, G., Kaser, A., Panaccione, R., Rubin, D., Shafran, I., O'Byrne, S., Geransar, P., James, A., Kaviya, A., Khalid, J.M.

Get full text